



January 23, 2021

The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

Dear Sir,

Subject: Outcome of Board Meeting.

This is with reference to our letter dated 16th January 2021.

At the meeting of the Board of Directors of the company held on 23rd January 2021 the following decisions have been taken:

- 1) Approved the Unaudited Standalone and Consolidated Financial Results alongwith Limited Review Report of the Company for the quarter ended on 31st December 2020.

This is for your information and records.

Thanking you

Yours Sincerely
For TRANSGENE BIOTEK LIMITED

DR. K. KOTESWARA RAO
CHAIRMAN & MANAGING DIRECTOR
DIN: 02287235

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2020

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Audited)	31.03.2020 (Audited)
1	Revenue from operations	15,65,499	-	-	35,754
2	Other income (net)	5,10,627	4,38,470	4,38,470	17,88,820
3	Total income (1 + 2)	20,76,126	4,38,470	4,38,470	18,24,574
4	EXPENSES				
	Cost of materials consumed	64,684	95,267	55,732	1,47,876
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-
	Employee benefits expense	6,55,322	7,51,572	7,14,017	28,95,496
	Finance costs	6,65,681	6,65,681	7,51,534	38,05,393
	Depreciation and amortisation expense	248,12,011	247,42,519	247,42,286	989,69,145
	Other expenses	10,43,125	9,18,266	7,87,947	56,29,036
	Total expenses	272,40,823	271,73,305	270,51,516	1114,46,946
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.33)	(0.35)	(0.35)	(1.45)
	Diluted (Rs.)	(0.33)	(0.35)	(0.35)	(1.45)

Notes:

1. TrabiORAL:

(a) We have successfully completed several in-vivo studies on Insulin in Canines and on GLP peptides during the quarter.

(b) We plan to restart animal studies held up during the Christmas and New year period on different molecules belonging to different pharma majors.

2. A wholly owned subsidiary of Transgene Biotech Ltd by the name of M/s PerORAL Bio Pvt Ltd has been registered with required formalities due to be completed soon.

3. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

4. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 23rd January 2021.

For TRANSGENE BIOTEK LIMITED


Dr. K. Koteswara Rao
Managing Director

Date: 23.01.2021
Place: Hyderabad



TRANSGENE BIOTEK LIMITED

Notes forming part of the Standalone financial statements

Other operating expenses

Particulars	For the Period ended Dec 31,2020
Power and fuel	34,206
Legal and Professional Charges	(1,41,010)
Annual Custody and issuer fee	-
Telephone Expenses	8,723
Municipality Tax	-
Patents Application fee	-
Independent Directros empannelment Fee	-
Interest and penalties	45,017
Testing Charges	-
ROC filing charges	-
Google drive	390
Conveyance	1,075
Bank charges	1,154
Advertisement Exp	3,500
Miscellaneous Expenses	3,500
Postage & Courier	-
Directros Sitting fee	15,000
Repairs and Maintenance	2,000
AGM VC Charges	-
Pollution Control	8,85,000
Printing & Stationary	-
ROC challan	4,000
Transport Charges	2,000
Website Service	-
Insurance Expenses	75,871
Customs & Clearing charges	28,123
Factory License fee	18,000
Software Expenses	25,000
Business Promotion Expenses	4,170
General Expenses	950
Forex Gain/(Loss)	24,776
Medical Expenses	1,680
Total	10,43,125

For TRANSGENE BIOTEK LIMITED


Dr.K.Koteswara Rao
Managing Director

FIXED ASSETS UP TO 31/12/2020

Opening

Sl. No	PARTICULARS	DEPRN. RATE %	GROSS BLOCK				DEPRECIATION				BLOCK	
			AS AT 30.09.2020	Addition during the Period	(Deletion) during the Period	AS AT 31.12.2020	Up to 30.09.2020	Depreciation on Additions	Depreciation on Deletions	for the Period ended 31.12.2020	Up to 31.12.2020	AS AT 31.12.2020
			Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
1	Land	-	6,55,796	-	-	6,55,796	-	-	-	-	6,55,796	6,55,796
2	Building	3.34	340,19,720	-	-	340,19,720	216,69,577	-	-	65,592	217,35,168	122,84,552
3	Buildings temporary	100.00	68,163	-	-	68,163	68,163	-	-	-	68,163	-
4	Computers	16.21	18,75,513	-	-	18,75,513	17,42,347	-	-	3,146	17,45,493	1,30,020
5	Electrical Equipments	4.75	102,98,850	-	-	102,98,850	101,73,848	-	-	39,502	102,13,350	85,500
6	Furniture	6.33	9,22,627	-	-	9,22,627	8,48,013	-	-	-	8,48,013	74,614
7	Office Equipments	4.75	185,76,575	-	-	185,76,575	176,52,518	-	-	-	176,52,518	9,24,057
8	Plant & Machinery	4.75	778,67,443	3,09,322	58,893	781,17,872	710,44,540	69,492	3,832	4,42,721	714,87,261	66,30,611
9	Vehicles	9.50	6,35,801	-	-	6,35,801	6,07,468	-	-	-	6,07,468	28,333
	Total (A)		1449,20,488	3,09,322	58,893	1451,70,917	1238,06,474	-	-	5,50,960	1243,57,434	208,13,483
	Intangible Assets											
1	Intellectual Property Rights	10.00	-	-	-	-	-	-	-	-	-	-
2	Technology	7.07	9301,18,554	-	-	9301,18,554	6892,69,494	-	-	242,43,077	7135,12,571	2166,05,983
3	Patents		7,56,803	-	-	7,56,803	1,64,426	-	-	17,974	1,82,400	5,74,403
	Capital Work in Progress-Buildings		-	-	-	-	-	-	-	-	-	-
	Total (B)		9193,53,810	-	-	9308,75,357	6894,33,920	-	-	242,61,051	7136,94,971	2171,80,386
	Total (A+B)		10468,66,516	-	58,893	10760,46,274	8132,40,394	-	-	248,12,011	8380,52,405	2379,93,869
								-	-	-	-	2625,55,451

[Handwritten Signature]



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2020

(Amount in Rs.)

Sr. No.	Particulars	Quarter Ended			Year Ended
		31.12.2020 (Unaudited)	30.09.2020 (Unaudited)	31.12.2019 (Audited)	31.03.2020 (Audited)
1	Revenue from operations	15,65,499	-	-	35,754
2	Other income (net)	5,10,627	4,38,470	4,38,470	17,88,820
3	Total income (1 + 2)	20,76,126	4,38,470	4,38,470	18,24,574
4	EXPENSES				
	Cost of materials consumed	64,684	95,267	55,732	1,47,876
	Changes in inventories of finished goods, work-in-progress and Stock-in-trade	-	-	-	-
	Employee benefits expense	6,55,322	7,51,572	7,14,017	28,95,496
	Finance costs	6,65,681	6,65,681	7,51,534	38,05,393
	Depreciation and amortisation expense	248,12,011	247,42,519	247,42,286	989,69,145
	Other expenses	10,43,125	9,18,266	7,87,947	56,29,036
	Total expenses	272,40,823	271,73,305	270,51,516	1114,46,946
5	Profit before exceptional items, share of profit from associate & joint venture and tax (3 - 4)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
6	Exceptional item (net)	-	-	-	-
7	Profit before tax (5 - 6)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
8	Tax expense				
	Tax adjustments for earlier years	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Total tax expense	-	-	-	-
9	Profit for the year (7 - 8)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
10	Other comprehensive income				
	A Items that will not be reclassified subsequently to profit or loss				
	(a) Remeasurements cost of post employment benefits	-	-	-	-
	Total other comprehensive income	-	-	-	-
11	Total comprehensive income for the year (9 + 10)	(251,64,697)	(267,34,835)	(266,13,046)	(1096,22,372)
12	Earnings per equity share				
	(Equity shares, par value of Rs. 10 each)	757,70,000	757,70,000	757,70,000	757,70,000
	Basic (Rs.)	(0.33)	(0.35)	(0.35)	(1.45)
	Diluted (Rs.)	(0.33)	(0.35)	(0.35)	(1.45)

Notes:

1. TrabiORAL:

(a) We have successfully completed several in-vivo studies on Insulin in Canines and on GLP peptides during the quarter.

(b) We plan to restart animal studies held up during the Christmas and New year period on different molecules belonging to different pharma majors.

2. A wholly owned subsidiary of Transgene Biotek Ltd by the name of M/s PerORAL Bio Pvt Ltd has been registered with required formalities due to be completed soon.

3. No. of investor complaints pending at the beginning of the quarter - 0; received complaint during the quarter - 0.

4. The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 23rd January 2021.

For TRANSGENE BIOTEK LIMITED


Dr. K. Koteswara Rao
Managing Director



Date: 23.01.2021
Place: Hyderabad

TRANSGENE BIOTEK LIMITED**Notes forming part of the Standalone financial statements****Other operating expenses**

Particulars	For the Period ended Dec 31,2020
Power and fuel	34,206
Legal and Professional Charges	(1,41,010)
Annual Custody and issuer fee	-
Telephone Expenses	8,723
Municipality Tax	-
Patents Application fee	-
Independent Directros empannelment Fee	-
Interest and penalties	45,017
Testing Charges	-
ROC filing charges	-
Google drive	390
Conveyance	1,075
Bank charges	1,154
Advertisement Exp	3,500
Miscellaneous Expenses	3,500
Postage & Courier	-
Directros Sitting fee	15,000
Repairs and Maintenance	2,000
AGM VC Charges	-
Pollution Control	8,85,000
Printing & Stationary	-
ROC challan	4,000
Transport Charges	2,000
Website Service	-
Insurance Expenses	75,871
Customs & Clearing charges	28,123
Factory License fee	18,000
Software Expenses	25,000
Business Promotion Expenses	4,170
General Expenses	950
Forex Gain/(Loss)	24,776
Medical Expenses	1,680
Total	10,43,125



FIXED ASSETS UP TO 31/12/2020

Sl. No.	PARTICULARS	DEPRN. RATE %	GROSS BLOCK				DEPRECIATION for the Period ended 31.12.2020				NET BLOCK	
			AS AT 30.09.2020	Addition during the Period	(Deletion) during the Period	AS AT 31.12.2020	Up to 30.09.2020	Depreciation on Additions	Depreciation on Deletions	Rs.	Up to 31.12.2020	AS AT 31.12.2020
			Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
1	Land	-	6,55,796	-	-	6,55,796	-	-	-	-	-	6,55,796
2	Building	3.34	340,19,720	-	-	340,19,720	216,69,577	-	-	216,69,577	217,35,168	122,84,552
3	Buildings temporary	100.00	68,163	-	-	68,163	68,163	-	-	68,163	68,163	-
4	Computers	16.21	18,75,513	-	-	18,75,513	17,42,347	-	-	17,42,347	17,45,493	1,30,020
5	Electrical Equipments	4.75	102,98,850	-	-	102,98,850	101,73,848	-	-	39,502	102,13,350	85,500
6	Furniture	6.33	9,22,627	-	-	9,22,627	8,48,013	-	-	-	8,48,013	74,614
7	Office Equipments	4.75	185,76,575	-	-	185,76,575	176,52,518	-	-	-	176,52,518	9,24,057
8	Plant & Machinery	4.75	778,67,443	3,09,322	58,893	781,17,872	710,44,540	69,492	3,832	4,42,721	714,87,261	66,30,611
9	Vehicles	9.50	6,35,801	-	-	6,35,801	6,07,468	-	-	-	6,07,468	28,333
	Total (A)		1449,20,488	3,09,322	58,893	1451,70,917	1238,06,474			5,50,960	1243,57,434	208,13,483
	Intangible Assets											
1	Intellectual Property Rights	10.00	-	-	-	-	-	-	-	-	-	-
2	Technology	7.07	9301,18,554	-	-	9301,18,554	6892,69,494	-	-	242,43,077	7135,12,571	2166,05,983
3	Patents		7,56,803	-	-	7,56,803	1,64,426	-	-	17,974	1,82,400	5,74,403
	Capital Work in Progress-Buildings											
	Total (B)		9193,53,810	-	-	9308,75,357	6894,33,920			242,61,051	7136,94,971	2171,80,386
	Total (A+B)		10468,66,516		58,893	10760,46,274	8132,40,394			248,12,011	8380,52,405	2379,93,869
												2414,41,437
												2625,55,451







Limited review report

To,
The Board of directors
M/s. Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Transgene Biotek Limited for the quarter ended 31 December 2020 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting". - ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.010114S


Manisha Dubey
Proprietor
M No.212664
Place: Hyderabad
Date: 23.01.2021






Limited Review Report

To,
The Board of directors
M/s. Transgene Biotech Limited
Hyderabad

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Transgene Biotech Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss for the quarter ended 31 December 2020 ("the Statement"), being submitted by the parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. Are view of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.
4. The Statement includes the results of the following entities


Name of the entity Relationship

- | | |
|---------------------------------|------------|
| 1. Transgene Biotech HK Limited | Subsidiary |
|---------------------------------|------------|



5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the Internal auditors referred to in paragraph below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed ,or that it contains any material misstatement.
6. We did not review the interim financial results of one subsidiary included in the Statement M/s Transgene Biotek HK Limited, whose interim financial results reflect total revenues of Rs. 0million, total net Loss after tax of Rs. 0 million and total comprehensive loss of Rs. 0 million, for the quarter ended 31 December 2020, as considered in the consolidated unaudited financial results.
7. M/s PERORAL BIO PRIVATE LIMITED vide CIN- U24230TG2020PTC147169 having subscribed and paid-up Capital of Rs.1,00,000/- (One Lakh only) was incorporated on 23.12.2020 as 100% owned Subsidiary of Transgene Biotek Limited .However the Transgene Biotek Limited has not paid the subscription amount yet. For consolidation purpose since the Subscribed capital has been not received the same has not been considered as on 31.12.2020.

For Manisha Dubey & Associates
Chartered Accountants
FRNo.0101149


Manisha Dubey
Proprietor
M No.212664
Place: Hyderabad
Date: 23.01.2021



Unique Document Identification Number (UDIN) for this document is

21212664AAAAN5426.